Skip to main content
Erschienen in: International Urogynecology Journal 6/2016

07.12.2015 | Original Article

Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence

verfasst von: Zuhal Ozen Tunay, Ozdemir Ozdemir, Damla Ergintürk Acar, Sabri Cavkaytar, Ebru Ersoy

Erschienen in: International Urogynecology Journal | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

To evaluate the effects of oral anticholinergic (OAC) drugs on tear secretion in women with overactive bladder over a 3-month follow-up period.

Methods

In this prospective study, 108 women with a diagnosis of overactive bladder were evaluated. All patients were examined ophthalmologically at baseline (day 0), and after 1 month (day 30) and 3 months (day 90) of OAC treatment. Tear film break-up time (BUT) and Schirmer 1 test results were recorded. The subjective complaints of the patients including dry mouth, and burning, dryness and foreign body sensation in the eyes, were also recorded. The chi-squared test or the paired sample t test as appropriate, was used for statistical analysis.

Results

The mean age of the patients was 51.8 ± 9.2 years (30 – 69 years). The most frequent subjective complaints were dry mouth and dry eyes and both complaints were significant on both day 30 and day 90. Both tear film BUT and Schirmer 1 test results were significantly lower on day 30 and day 90. Dry eye measurement values worsened with prolongation of OAC treatment (p = 0.037 and p = 0.012 for BUT, and p = 0.046 and p = 0.035 for Schirmer 1 test, on day 30 and day 90, respectively).

Conclusions

OAC treatment in women with overactive bladder significantly and progressively affects tear secretion.
Literatur
1.
Zurück zum Zitat Gani J, Perlis N, Radomski SB (2012) Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J 6:53–58PubMedPubMedCentral Gani J, Perlis N, Radomski SB (2012) Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J 6:53–58PubMedPubMedCentral
2.
Zurück zum Zitat Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348CrossRefPubMed Feinberg M (1993) The problems of anticholinergic adverse effects in older patients. Drugs Aging 3:335–348CrossRefPubMed
3.
Zurück zum Zitat Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54:806–815CrossRefPubMedPubMedCentral Cetinel B, Onal B (2013) Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol 54:806–815CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chapple CR, Nilvebrant L (2002) Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3:75–81CrossRefPubMed Chapple CR, Nilvebrant L (2002) Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 3:75–81CrossRefPubMed
5.
Zurück zum Zitat Lachkar Y, Bouassida W (2007) Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18:129–133CrossRefPubMed Lachkar Y, Bouassida W (2007) Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol 18:129–133CrossRefPubMed
6.
Zurück zum Zitat Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Chet de Groat W, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578CrossRefPubMedPubMedCentral Abrams P, Andersson KE, Buccafusco JJ, Chapple C, Chet de Groat W, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, Wein AJ (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Lemp MA (2008) Advances in understanding and managing dry eye disease. Am J Ophthalmol 146:350–356CrossRefPubMed Lemp MA (2008) Advances in understanding and managing dry eye disease. Am J Ophthalmol 146:350–356CrossRefPubMed
8.
Zurück zum Zitat Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14:595–597CrossRefPubMed Kato K, Furuhashi K, Suzuki K, Murase T, Sato E, Gotoh M (2007) Overactive bladder and glaucoma: a survey at outpatient clinics in Japan. Int J Urol 14:595–597CrossRefPubMed
9.
Zurück zum Zitat Eskandar OS, Eckford SD, Whittaker KW (2005) Treatment of overactive bladder (OBA) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol 25:419–421CrossRefPubMed Eskandar OS, Eckford SD, Whittaker KW (2005) Treatment of overactive bladder (OBA) with anti-cholinergic drugs and the risk of glaucoma. J Obstet Gynaecol 25:419–421CrossRefPubMed
10.
Zurück zum Zitat Yaycioglu RA, Yaycioglu O, Akova YA, Guvel S, Ozkardeş H (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59:588–592CrossRefPubMedPubMedCentral Yaycioglu RA, Yaycioglu O, Akova YA, Guvel S, Ozkardeş H (2005) Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 59:588–592CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U (2014) The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J 25:1479–1482CrossRefPubMed Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U (2014) The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J 25:1479–1482CrossRefPubMed
12.
Zurück zum Zitat Yayla EM, Yavuz E, Bilge U, Keskin A, Binen E (2015) Drugs with anticholinergic side-effects in primary care. Niger J Clin Pract 18(1):18–21PubMed Yayla EM, Yavuz E, Bilge U, Keskin A, Binen E (2015) Drugs with anticholinergic side-effects in primary care. Niger J Clin Pract 18(1):18–21PubMed
13.
Zurück zum Zitat Wong J, Lan W, Ong LM, Tong L (2011) Non-hormonal systemic medications and dry eye. Ocul Surf 9:212–226CrossRefPubMed Wong J, Lan W, Ong LM, Tong L (2011) Non-hormonal systemic medications and dry eye. Ocul Surf 9:212–226CrossRefPubMed
Metadaten
Titel
Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence
verfasst von
Zuhal Ozen Tunay
Ozdemir Ozdemir
Damla Ergintürk Acar
Sabri Cavkaytar
Ebru Ersoy
Publikationsdatum
07.12.2015
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 6/2016
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-015-2911-6

Weitere Artikel der Ausgabe 6/2016

International Urogynecology Journal 6/2016 Zur Ausgabe

Urogynecology digest

Urogynecology digest

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Menopausale Hormontherapie für Frauen über 65?

07.05.2024 Klimakterium und Menopause Nachrichten

In den USA erhalten nicht wenige Frauen auch noch im Alter über 65 eine menopausale Hormontherapie. Welche positiven und negativen gesundheitlichen Konsequenzen daraus möglicherweise resultieren, wurde anhand von Versicherungsdaten analysiert.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.